Management team

Frans Wuite, MD, MBA

Interim CEO & Vice Chairman of the Board

Frans Wuite MD, MBA has been a Herantis Board member since 2014 and vice chairman since April 2020. He has a long international career with a track record of successfully commercializing and growing pharmaceutical and biotech businesses. Frans Wuite was CEO of Acesion Pharma ApS until 2020. Prior to this, he was CEO and President of Oncos Therapeutics Oy, COO of Warren Pharmaceuticals Inc, Co-founder and Board Director of Araim Pharmaceuticals Inc, and member of Amgen’s European management team, where he was in charge of establishing the anaemia franchise. Before Amgen, he was President of Pharmacia-Leiras BV, a joint venture for marketing products with novel dose delivery technologies for women’s healthcare in Europe. Frans is also a current board director of Healthcap VII GP SA.

Tone Kvåle

Chief Financial Officer

Tone Kvåle is a seasoned financial executive with 25 years of experience and a stong track record in the biotech and life sciences industry.  Most recently, she was CFO at Nordic Nanovector, a publicly listed company in Norway, for 7 years, and prior to that, she held CFO roles at NorDiag (publicly listed company), Kavli Holding, Dynal Biotech, as well as senior management positions at Invitrogen/Life Technologies, in US, now part of Thermo Fisher.  In these roles, she helped raise over EUR 200m in financing, was involved in several trade sales, M&A and licensing deals, and was responsible for financial reporting under various reporting standards including US GAAP and IFRS. She currently serves as director of the board and chair of the audit committee of Bonesupport AB, Sweden. Tone has a diploma in finance and administration from UiT The Arctic University of Norway, Harstad.

Antti Vuolanto

Chief Operating Officer

Antti Vuolanto, DSc, joined Herantis Pharma Plc in February 2018. He has vast experience in biological drug development, in-vitro diagnostics, and building start-up companies. Antti has in-depth knowledge of gene therapy-based drug development including scientific, CMC, and clinical trial expertise. Previously he served as COO at Valo Therapeutics, as Executive Vice President at Targovax ASA, and COO and co-founder at Oncos Therapeutics Ltd that merged with Targovax in 2015. He has also held senior management positions at other biotech companies. Dr. Vuolanto graduated as Doctor in Science in Technology at Aalto University, Finland, in 2004 in bioprocess engineering.

Henri Huttunen

Chief Scientific Officer

Henri Huttunen co-founded Herantis Pharma Plc. in 2008 and served as the company’s founding CEO for the first two years. Dr. Huttunen is currently the Chief Scientific Officer of Herantis. Dr. Huttunen has previously held research positions at the University of Helsinki, Orion Pharma, and Massachusetts General Hospital, Harvard Medical School (USA). Dr. Huttunen has a PhD in biochemistry from the University of Helsinki and 25 years of experience in neuroscience research. While he was an adjunct professor, Dr. Huttunen lead an academic research group focusing on molecular mechanisms of neurodegenerative diseases at the Neuroscience Center, University of Helsinki.

Sigrid Booms

Head of Regulatory Affairs & Compliance

Sigrid Booms has served as Director of Clinical Development of Herantis since August 2011 and was promoted to Head of Regulatory Affairs & Compliance in December 2020. Mrs. Booms has more than 25 years of experience in global development of pharmaceuticals for human use, with previous positions in regulatory affairs at Orion Pharma and at a global clinical CRO as Director, Regulatory Affairs. During her career, she was involved in several drug development projects in the CNS therapeutic area and is currently the study director for the CDNF (protein) clinical development in Parkinson’s disease. Over the years she has become a specialist in regulatory aspects for nonclinical and early phase clinical development. Mrs. Booms holds a Licentiate in pharmacy from the University of Utrecht in the Netherlands.

Charlotte Videbæk

Vice President Clinical Development

Charlotte Videbæk, MD is the Vice President Clinical Development since April 2022. Dr. Videbæk is a board-certified neurologist from Copenhagen with a track record from international pharmaceutical companies developing therapies for neurodegenerative diseases, including Parkinson’s disease.  She has worked at Novartis and Roche in Basel prior to joining Lundbeck in Copenhagen in various positions including VP Corporate Project Management R&D. Lately she has been with earlier stage companies and focused on entrepreneurship. Charlotte is a board director of Cessatech A/S, Tissue-Link and consultant and founder of C-ApS.